Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.

10007 Background: Masitinib is an oral tyrosine kinase inhibitor with greater in vitro activity and selectivity than imatinib against wild-type and juxtamembrane mutations of KIT (Dubreuil, 2009, P...